162 related articles for article (PubMed ID: 34602371)
1. SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML.
Saxena K; DiNardo C; Daver N; Konopleva M
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):133-139. PubMed ID: 34602371
[TBL] [Abstract][Full Text] [Related]
2. Harnessing Apoptosis in AML.
Saxena K; DiNardo C; Daver N; Konopleva M
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S61-S64. PubMed ID: 32862872
[TBL] [Abstract][Full Text] [Related]
3. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Dhakal P; Bates M; Tomasson MH; Sutamtewagul G; Dupuy A; Bhatt VR
Blood Rev; 2023 May; 59():101036. PubMed ID: 36549969
[TBL] [Abstract][Full Text] [Related]
6. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
Forsberg M; Konopleva M
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara F
Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
[No Abstract] [Full Text] [Related]
9. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
11. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
[TBL] [Abstract][Full Text] [Related]
12. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
15. Prospects for Venetoclax in Myelodysplastic Syndromes.
Garcia JS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
[TBL] [Abstract][Full Text] [Related]
16. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in acute myeloid leukemia - current and future directions.
Lachowiez C; DiNardo CD; Konopleva M
Leuk Lymphoma; 2020 Jun; 61(6):1313-1322. PubMed ID: 32031033
[TBL] [Abstract][Full Text] [Related]
18. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
Choi JH; Bogenberger JM; Tibes R
Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
[TBL] [Abstract][Full Text] [Related]
20. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
Aldoss I; Marcucci G
Chin Clin Oncol; 2019 Oct; 8(S1):S25. PubMed ID: 31684734
[No Abstract] [Full Text] [Related]
[Next] [New Search]